The Efficacy and Safety of Medicurtain® in Patients With Hysteroscopy (Pivotal Study)

Tissue Adhesion, Surgery-Induced Clinical Trial

Official title:

A Placebo Comparative, Evaluator Blinded, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of Medicurtain® in Patients With Hysteroscopy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04638855
• Other study ID #: UMT2009-SP-ASMC-0401
• Status: Completed
• Phase: N/A
• Start date: September 8, 2010
• Est. completion date: December 3, 2011

Study information

• Verified date: September 2021
• Source: Shin Poong Pharmaceutical Co. Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was designed to assess the safety and efficacy of MEDICURTAIN, an adhesion barrier in patients who underwent hysteroscopy with uterine polyp or endometrial myoma or missed abortion (uterine lesion suspected to be associated with pregnancy) or intrauterine adhesion. Adhesion formation in both groups was evaluated by the grading scale and photographs taken during the follow up to evaluate the safety and efficacy of the product.

Description:

This study was designed as a multi-center, randomized, evaluator-blinded and placebo-comparative study. A woman aged 20-80 years scheduled for the hysteroscopy was eligible to participate in the study. Subject screening was conducted for the subject who signed an informed consent form. Subjects who met the inclusion/exclusion criteria were randomly assigned into either treatment or no-treatment control group. Follow-up visits were performed at 1 week (Visit 2) and 4 weeks (Visit 3) after the index surgery. Telephone call is made between 1 to 2 weeks prior to the Visit 3 for the information for the follow-up visit and check-up. At Visit 2 (at Week 1 after the index surgery, a window of ± 2 days was allowed), assessments to identify adverse events and general health conditions, and surgery satisfaction survey were performed. At Visit 3 (at Week 4 ± 4 days), adverse event assessments and general satisfaction survey were performed, and adhesion formations and grades were evaluated. The presence or absence of adhesions, and their grades at Visit 3 (at Week 4 ± 4 days) were assessed in an evaluator-independent manner. Adhesion formations rate (Primary endpoint) and adhesion grade(secondary endpoint) were assessed at Week 4 after the index surgery (Visit 3), based on the video clips and still images captured via a video monitor during a second-look hysteroscopy, by inserting the hysteroscope (5 -10 mm diameter) into the uterine through the vagina; and graded in an evaluator-blinded manner by an independent evaluator, who did not take part in the index surgery or application of Medicurtain®. Intrauterine adhesion grades were assessed by using the American Fertility Society (AFS) adhesion score established in 1988. It was classified as 4 grading scales (0, 1, 2 and 3 grade). Grade 0 (none) means no adhesion, while Grade 1 to Grade 3 means there are adhesions and severity increased with the grade. Adhesion formation rate and grade in the treated or in the non-treated control groups were compared and evaluated using the Grade 0 to 3 adhesion scoring system.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 223
• Est. completion date: December 3, 2011
• Est. primary completion date: December 3, 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Woman who is between 20~80 years of age.

2. Woman who is reserved elective hysteroscopy for

• Uterine polyp
• Uterine (endometrium) myoma
• Missed miscarriage (uterine lesion suspected to be associated with pregnancy)
• Adhesion in uterine

3. Woman who signed an informed consent form prior to the investigation.

Exclusion Criteria:

1. Presence of tumor or inflammatory disease in other organs.

2. Subject who is not eligible for anesthesia or re-operation due to other disease confirmed by investigator.

3. Subject who is not eligible for re-operation or hysteroscopy

4. Any condition which made a subject unsuitable for inclusion in the discretion of the Investigator will be excluded.

Related Conditions & MeSH terms

• Intrauterine Synechiae
• Tissue Adhesion, Surgery-Induced
• Tissue Adhesions

Intervention

Device:
• Medicurtain®
Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after hysteroscopy surgery)
• Placebo
No device after hysteroscopy surgery

Locations

Country	Name	City	State
Korea, Republic of	Gangnam Severance Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Shin Poong Pharmaceutical Co. Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Outcome Measure: comparison between treated group and untreated control group for the adhesion rate	Adhesion rate: {(number of subjects occurred adhesion formation for each group)/ (number of subjects for each group)} * 100	4 weeks
Secondary	Comparison of Adhesion Grade between treated group and untreated control group	Adhesive grade evaluation standards are classified into Grade 0(Non), Grade 1(Mild), Grade 2(Moderate), Grade 3(Severe).	4 weeks
Secondary	The incidence rate of adverse events	Safety and tolerability by collecting adverse events (AEs)	follow up to 4 weeks
Secondary	The incidence rate of adverse drug reaction	Safety and tolerability by collecting adverse drug reaction (ADRs)	follow up to 4 weeks
Secondary	The incidence rate of serious adverse events	Safety and tolerability by collecting serious adverse events (SAEs)	follow up to 4 weeks